What is Surmodics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Surmodics's interest expense for the
three
months ended in Dec. 2024 was $ -0.9 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.5 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Surmodics's Operating Income for the
three
months ended in Dec. 2024 was $ -2.5 Mil. Surmodics's Interest Expense for the
three
months ended in Dec. 2024 was $ -0.9 Mil.
Surmodics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Surmodics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surmodics (NAS:SRDX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Surmodics's Interest Expense for the
three
months ended in Dec. 2024 was $-0.9 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $-2.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $32.0 Mil.
Surmodics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
| Surmodics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Surmodics Business Description
Traded in Other Exchanges
N/A
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Executives
| Timothy J. Arens |
officer: General Manager - IVD |
9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344 |
| Jose H Bedoya |
director |
|
| David Dantzker |
other: See Explanation of Responses |
80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021 |
| Kalich Ronald B Sr |
director |
|
| Gary R Maharaj |
director, officer: President & CEO |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Joseph J. Stich |
officer: VP, Corp Dev & Strat Planning |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Charles W Olson |
officer: General Manager |
|
| John D. Manders |
officer: Corporate Controller |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Gordon S. Weber |
officer: Sr. VP of Legal, GC and Sec. |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Nusrath Sultana |
officer: VP, Clinical Affairs |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Lisa Wipperman Heine |
director |
1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077 |
| Teri Woodwick Sides |
officer: Senior VP and CMO |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
| Gregg S Sutton |
officer: VP of Research and Development |
6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369 |
| Susan E Knight |
director |
9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437 |
| Bryan K Phillips |
officer: Dep. Gen. Counsel & Corp. Sec. |
9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRDX has been successfully added to your 